NKTXHealthcare · BiotechnologyNKTX Stock Forecast: Nkarta, Inc. Price Predictions for 2026-2027
The 7 Wall Street analysts covering Nkarta, Inc. hold a median 12-month price target of $11 — +411.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 57 of 100 as at 1 Aug 2026 — in the upper half.
NKTX stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Nkarta, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (72): Reported profit is backed by cash, and the company is not expanding recklessly.
Value (18): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own Nkarta, Inc. — and when they’d sell — is the membership.
NKTX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on NKTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +411.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 May 2026 | Needham | Reiterates | Buy | $11 |
| 31 Mar 2026 | Mizuho | Maintains | Outperform | — |
| 26 Mar 2026 | Needham | Maintains | Buy | — |
| 11 Nov 2025 | Stifel | Maintains | Buy | — |
| 14 Aug 2025 | Stifel | Maintains | Buy | — |
| 13 Aug 2025 | Needham | Reiterates | Buy | — |
| 10 June 2025 | Mizuho | Maintains | Outperform | — |
| 15 May 2025 | Needham | Maintains | Buy | — |
| 15 May 2025 | William Blair | Downgrade | Market Perform | — |
| 9 Apr 2025 | Needham | Reiterates | Buy | — |
| 27 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Mar 2025 | Needham | Reiterates | Buy | — |
| 27 Mar 2025 | Stifel | Maintains | Buy | — |
| 21 Nov 2024 | Mizuho | Maintains | Outperform | — |
| 11 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 Nov 2024 | Needham | Maintains | Buy | — |
| 15 Aug 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 14 Aug 2024 | Needham | Reiterates | Buy | — |
| 14 Aug 2024 | Raymond James | Upgrade | Strong Buy | — |
| 24 July 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
NKTX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Nkarta, Inc. (NKTX) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −1.5×
- Price / sales
- —
- Price / book
- 0.5×
- EV / EBITDA
- 0.1×
Cheaper than 83% of US stocks
Cheaper than 84% of US stocks
Cheaper than 61% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −30.1%
- Return on assets
- −17.1%
- Dividend yield
- —
Higher than 27% of US stocks
Higher than 21% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
NKTX vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NKTX appears on the weeks it earns a place.
Frequently asked questions about NKTX stock
What is the NKTX stock price forecast for 2026-2027?
The 7 Wall Street analysts covering Nkarta, Inc. have a median 12-month price target of $11, with estimates ranging from $9 to $16. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is NKTX stock a buy right now?
Of the 7 analysts covering Nkarta, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nkarta, Inc. 57 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank NKTX?
As at 1 Aug 2026, Nkarta, Inc. ranks 57 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (72 of 100).
Will NKTX stock go up?
No one can know that. What the data says: the median 12-month target from 7 analysts implies +411.6% from the last close, and Ticker Nerd's factor model ranks Nkarta, Inc. 57 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the NKTX stock forecast for 2030?
No analyst covering Nkarta, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NKTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $16 over the next 12 months.
How has NKTX stock performed over the past year?
Nkarta, Inc. returned +1.4% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Nkarta, Inc. do?
Nkarta Inc. is a pioneering biotechnology company focused on harnessing the power of natural killer (NK) cells to develop transformative cell therapies aimed at treating cancer.
About Nkarta, Inc.
Nkarta Inc. is a pioneering biotechnology company focused on harnessing the power of natural killer (NK) cells to develop transformative cell therapies aimed at treating cancer. As a leader in the immunotherapy sector, Nkarta’s primary function is to advance the frontiers of cellular therapy by engineering NK cells to recognize and destroy cancer cells. The company’s innovative approach involves enhancing the innate abilities of NK cells to improve their efficacy, persistence, and applicability across various forms of cancer. Nkarta Inc. operates primarily in the biotechnology and healthcare industries, focusing on clinical-stage developments that can lead to groundbreaking treatments. It collaborates with academic institutions and partners within the biotech landscape to drive research and development efforts. The significance of Nkarta in the market stems from its potential to revolutionize cancer treatment paradigms, enabling more effective and less intrusive therapeutic options for patients. Founded with a mission to improve treatment outcomes, Nkarta Inc. represents a critical piece of the broader immunotherapy movement, contributing to the growing arsenal of cell-based cancer therapies shaping modern oncology.
CEO Mr. Paul J. Hastings · 108 employees · United States · https://www.nkartatx.com